Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 106-112

  Brugaletta, Salvatore ^a,b   Radu, Maria D ^a   Garcia Garcia, Hector M ^a,b,c   Heo, Jung Ho ^a   Farooq, Vasim ^a   Girasis, Chrysafios ^a   van Geuns, Robert Jan ^a   Thuesen, Leif ^d   McClean, Dougal ^e   Chevalier, Bernard ^f   Windecker, Stephan ^g   Koolen, Jacques ^h   Rapoza, Richard ⁱ   Miquel Hebert, Karine ⁱ   Ormiston, John ^j   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CARDIALYSIS   (Netherlands)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e CHRISTCHURCH HOSPITAL   (New Zealand)

^f INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^g UNIVERSITY OF BERN   (Switzerland)

^h CATHARINA HOSPITAL   (Netherlands)

ⁱ ABBOTT VASCULAR   (United States)

^j AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

Bioresorbable vascular scaffold; Neointima; OCT

Indexed keywords

ALGORITHM; ARTERIAL WALL THICKNESS; ARTICLE; BIODEGRADABLE IMPLANT; BIORESORBABLE VASCULAR SCAFFOLD; CONTROLLED STUDY; FOLLOW UP; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; NEOINTIMA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TISSUE DISTRIBUTION; WOUND HEALING;

ABSORBABLE IMPLANTS; ALGORITHMS; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DELAYED-ACTION PREPARATIONS; ENDOVASCULAR PROCEDURES; FIBROSIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEOINTIMA; POLYESTERS; PREDICTIVE VALUE OF TESTS; SIROLIMUS; TIME FACTORS; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84857032015     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.008     Document Type: Article

References (30)

1. Garg S., Serruys P.W. Coronary stents: looking forward. J Am Coll Cardiol 2010, 56:S43-S78.
2. Garg S., Serruys P.W. Coronary stents: current status. J Am Coll Cardiol 2010, 56:S1-S42.
3. Ramcharitar S., Gonzalo N., van Geuns R.J., Garcia-Garcia H.M., Wykrzykowska J.J., Ligthart J.M., et al. First case of stenting of a vulnerable plaque in the secritt i trial-the dawn of a new era?. Nat Rev Cardiol 2009, 6:374-378.
4. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
5. Finn A.V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M.C., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
6. Onuma Y., Serruys P.W., Perkins L.E., Okamura T., Gonzalo N., Garcia-Garcia H.M., et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the absorb trial. Circulation 2010, 122:2288-2300.
7. Serruys P.W., Ormiston J.A., Onuma Y., Regar E., Gonzalo N., Garcia-Garcia H.M., et al. A bioabsorbable everolimus-eluting coronary stent system (absorb): 2-year outcomes and results from multiple imaging methods. Lancet 2009, 373:897-910.
8. Serruys P.W., Onuma Y., Ormiston J.A., de Bruyne B., Regar E., Dudek D., et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010, 122:2301-2312.
9. Serruys P.W., Onuma Y., Dudek D., Smits P.C., Koolen J., Chevalier B., et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011, 58:1578-1588.
10. Ormiston J.A., Serruys P.W., Regar E., Dudek D., Thuesen L., Webster M.W., et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (absorb): a prospective open-label trial. Lancet 2008, 371:899-907.
11. Ewaschuk J.B., Naylor J.M., Zello G.A. D-lactate in human and ruminant metabolism. J Nutr 2005, 135:1619-1625.
12. Sihan K., Botha C., Post F., de Winter S., Gonzalo N., Regar E., et al. Fully automatic three-dimensional quantitative analysis of intracoronary optical coherence tomography: method and validation. Catheter Cardiovasc Interv 2009, 74:1058-1065.
13. Prati F., Regar E., Mintz G.S., Arbustini E., Di Mario C., Jang I.K., et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010, 31:401-415.
14. Gonzalo N., Serruys P.W., Okamura T., Shen Z.J., Onuma Y., Garcia-Garcia H.M., et al. Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall: a systematic quantitative approach. Heart 2009, 95:1913-1919.
15. Okamura T., Garg S., Gutierrez-Chico J.L., Shin E.S., Onuma Y., Garcia H.M., et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an oct ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the absorb clinical trial. EuroIntervention 2010, 932-938.
16. Regar E., Leeuwen AMGJv, Serruys P.W. Optical coherence tomography in cardiovascular research. Informa Healthcare 2007.
17. Gonzalo N., Serruys P.W., Garcia-Garcia H.M., van Soest G., Okamura T., Ligthart J., et al. Quantitative ex vivo and in vivo comparison of lumen dimensions measured by optical coherence tomography and intravascular ultrasound in human coronary arteries. Rev Esp Cardiol 2009, 62:615-624.
18. Brugaletta S., Gomez-Lara J., Diletti R., Farooq V., Jan van Geuns R., de Bruyne B., et al. Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the absorb and spirit trials. Catheter Cardiovasc Interv 2011, Epub ahead of print.
19. de Jaegere P., Mudra H., Figulla H., Almagor Y., Doucet S., Penn I., et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the multicenter ultrasound stenting in coronaries study (music study). Eur Heart J 1998, 19:1214-1223.
20. Guagliumi G., Costa M.A., Sirbu V., Musumeci G., Bezerra H.G., Suzuki N., et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the harmonizing outcomes with revascularization and stents in acute myocardial infarction (horizons-ami) trial. Circulation 2011, 123:274-281.
21. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003, 41:15S-22S.
22. Virmani R., Burke A.P., Farb A., Kolodgie F.D. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47:C13-C18.
23. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997, 336:1276-1282.
24. Stone G.W., Maehara A., Lansky A.J., de Bruyne B., Cristea E., Mintz G.S., et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011, 364:226-235.
25. Takarada S., Imanishi T., Kubo T., Tanimoto T., Kitabata H., Nakamura N., et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis 2009, 202:491-497.
26. Holmes D.R., Kereiakes D.J., Garg S., Serruys P.W., Dehmer G.J., Ellis S.G., et al. Stent thrombosis. J Am Coll Cardiol 2010, 56:1357-1365.
27. Khattab A., Windecker S. Vascular restoration therapy: what should the clinical and angiographic measures for success be?. EuroIntervention 2009, 5(Supplement F):F49-F57.
28. Farooq V., Gogas B.D., Serruys P.W. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv 2011, 4:195-205.
29. Kim B.K., Kim J.S., Ko Y.G., Choi D., Jang Y., Hong M.K. Correlation of angiographic late loss with neointimal coverage of drug-eluting stent struts on follow-up optical coherence tomography. Int J Cardiovasc Imaging 2011.
30. Kim J.S., Wallace-Bradley D., Alviar C.L., Conditt G., Milewski K., Afari M.E., et al. Correlation of angiographic late loss with neointimal proliferation in stents evaluated by oct and histology in porcine coronary arteries. JACC Cardiovasc Imaging 2011, 4:1002-1010.